The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Category Archives: Wayne Schnarr

Q2 Canadian Healthcare Review Shows Biotech Financing Weakness but Some M&A and Regulatory Wins

Data in the Q2 2010 Canadian Healthcare Review from the Equicom Group (co-authored by James Smith, Vice President Healthcare at Equicom and myself) shows a continuation of the weakness in biotech financing that was outlined in last week’s Toronto presentation of Ernst & Young’s Beyond Borders global biotech report. The public Canadian development stage companies raised [...]

Biotech’s Murky IPO Window Increases M&A Attractiveness

A recent press release from Burrill & Company points out that only 1 of 8 U.S. biotech IPOs in 2010 is currently trading above its IPO price. IMRIS was the last Canadian biotech IPO, completed in November 2007 at $6.00, and it is currently trading at $5.50 after dipping under $2 in late 2008. Facing these [...]

Biotech IPOs Past — 10 Years After the Biotech Venture Capital Boom of 1999-2001

You often hear people in this industry reminiscing about biotech booms and praying for another IPO window to open. The three most recent boom/windows were in 1995-1996, 1999-2001 and 2003-2005, each of which was impacted by both positive external market forces and a driving factor within biotech. The most spectacular boom/window was in 1999-2001, with [...]

Welcome to New Cross-Border Biotech Blog Contributor Wayne Schnarr

I am very excited to introduce Wayne Schnarr as a contributor to the Cross-Border Biotech Blog. Wayne has a ton of industry experience and always has smart things to say, as you will see for yourselves in a minute. Welcome!

Follow

Get every new post delivered to your Inbox.

Join 92 other followers